Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 15/20 | 0.70 |
| ▸ | CCNE1 | P24864 | 13/20 | 0.70 |
| ▸ | CDK1 | P06493 | 12/20 | 0.70 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.52 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.51 |
| ▸ | CDK7 | P50613 | 1/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
| ▸ | CCNH | P51946 | 1/20 | 0.51 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17352552 | 0.90 | CCNE1 (0.69) | CDK2CCNE1CDK1CCNA2CCNA1 | |
| SCHEMBL17352693 | 0.86 | CDK2 (0.70) | CDK2CCNE1CDK1CCNA2CCNA1 | |
| SCHEMBL15940671 | 0.86 | CDK1 (0.65) | CDK2CCNE1CDK1PDGFRACCNA2 | |
| SCHEMBL15941106 | 0.85 | CCNE1 (0.70) | CDK2CCNE1CDK1PDGFRACCNA2 | |
| SCHEMBL17352546 | 0.85 | CCNE1 (0.71) | CDK2CCNE1CDK1CCNA2CCNA1 | |
| SCHEMBL17352678 | 0.85 | CCNE1 (0.73) | CDK2CCNE1CDK1CCNA2CCNA1 | |
| SCHEMBL15941067 | 0.85 | CDK2 (0.73) | CDK2CCNE1CDK1PDGFRACCNA2 | |
| SCHEMBL15940857 | 0.85 | CDK2 (0.72) | CDK2CCNE1CDK1PDGFRACCNA2 | |
| SCHEMBL15941047 | 0.84 | CDK2 (0.69) | CDK2CCNE1CDK1PDGFRACCNA2 | |
| SCHEMBL17352577 | 0.84 | CCNE1 (0.71) | CDK2CCNE1CDK1CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150368248-A1 | 2-SUBSTITUTED-6-BIARYLMETHYLAMINO-9-CYCLOPENTYL-9H-PURINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS | BIOPATTERNS S.R.O. (CZ) | 2015-12-24 | — | — | US | disclosed |
| EP-2953951-A2 | 2-SUBSTITUTED-6-BIARYLMETHYLAMINO-9-CYCLOPENTYL-9H-PURINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS | Univerzita palackeho V Olomouci (CZ) | 2015-12-16 | — | — | EP | disclosed |
| WO-2014121764-A2 | 2-SUBSTITUTED-6-BIARYLMETHYLAMINO-9-CYCLOPENTYL-9H-PURINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2014-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368248-A1 | 2-SUBSTITUTED-6-BIARYLMETHYLAMINO-9-CYCLOPENTYL-9H-PURINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS | ENTPD5, PNP, HCCS | CDK2 356/4885CCNE1 2605/4885CDK1 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.